Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5831864 | 0.83 | TDP1 (0.42) | EP300ALDH1A1KDM4EGLAMAPT | |
| SCHEMBL18254504 | 0.82 | EP300 (0.49) | EP300ALDH1A1KDM4EGLAMAPT | |
| SCHEMBL17717907 | 0.81 | EP300 (0.48) | EP300ALDH1A1KDM4EGLAMAPT | |
| SCHEMBL5831940 | 0.81 | EP300 (0.43) | EP300ALDH1A1KDM4EGLAMAPT | |
| SCHEMBL7525758 | 0.79 | EP300 (0.43) | EP300ALDH1A1KDM4EGLAMAPT | |
| SCHEMBL7844009 | 0.78 | EP300 (0.66) | EP300ALDH1A1GAAPOLBMEN1 | |
| SCHEMBL5831471 | 0.77 | EP300 (0.39) | EP300ALDH1A1KDM4EGLAMAPT | |
| SCHEMBL9482802 | 0.77 | EP300 (0.41) | EP300ALDH1A1KDM4EGLAMAPT | |
| SCHEMBL7713013 | 0.76 | UPP1 (0.37) | UPP1ALDH1A1 | |
| SCHEMBL17717901 | 0.75 | EP300 (0.50) | EP300ALDH1A1KDM4EGLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0716603-A4 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | UAB RESEARCH FOUNDATION (US) | 2000-10-04 | — | — | EP | claimed |
| EP-0716603-A1 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | THE UAB RESEARCH FOUNDATION (US) | 1996-06-19 | — | — | EP | claimed |
| EP-0526537-B1 | 5-BENZYL BARBITURATE DERIVATIVES | UNIV BROWN RES FOUND (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1995005180-A1 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | THE UAB RESEARCH FOUNDATION (US) | 1995-02-23 | — | — | WO | claimed |
| US-5141943-A | Water soluble uridine phosphorylase inhibitors, reducing toxicity and anemia of antiviral drugs | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1992-08-25 | — | — | US | claimed |
| US-6992072-B2 | Combating side-effects | PHARMA NORD APS (DK) | 2006-01-31 | — | — | US | disclosed |
| US-20040138157-A1 | Combating side-effects | PHARMA NORD APS (DK) | 2004-07-15 | — | — | US | disclosed |
| EP-0716603-A4 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | UAB RESEARCH FOUNDATION (US) | 2000-10-04 | — | — | EP | disclosed |
| US-5723449-A | ANTISECRETORY AGENTS AND ANTICARCINOGENIC AGENTS | THE UAB RESEARCH FOUNDATION (US) | 1998-03-03 | — | — | US | disclosed |
| US-5567689-A | CONCURRENT ADMINISTERING MIXTURE OF URIDINE PHOSPHORYLASE INHIBITOR, URIDINE SECRETION INHIBITOR AND(OR) COMPOUNDWHICH COMPETES WITH URIDINE IN RENAL TRANSPORTATION MECHANISM | THE UAB RESEARCH FOUNDATION (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0716603-A1 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | THE UAB RESEARCH FOUNDATION (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1995005180-A1 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | THE UAB RESEARCH FOUNDATION (US) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138157-A1 | Combating side-effects | POLRMT, TK2, POLM | EP300 4369/4885UPP1 185/4885ALDH1A1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.